Are large simple trials for dementia prevention possible?
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“and behavioural deficits, [18] and removal of brain amyloid [assessed by positron emission tomography (PET) or cerebrospinal fluid (CSF) studies] has yet to correlate with clinically meaningful improvements in cognition.”
BackgroundThe Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 4×
“[20] The earliest physiological change in human carriers of APOE ε4 is vascular dysfunction, and in apoe ε4 animal models early degeneration of vascular endothelial cells and pericytes.”
BackgroundInfluentialMitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659 · cited 1×
“[13,14] Because of differences in these characteristics, trials recruiting participants with MCI have had varying progression to dementia.”
BackgroundMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Self-citationVascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · cited 1×
“[20,23] Vascular damage leads to blood brain barrier breakdown, parenchymal accumulation of neurotoxic moieties, inflammation and synaptic dysfunction and accumulation of Aβ and tau through failure to clear proteins along perivascular spaces and through aberrant metabolism.”
BackgroundSelf-citationAlzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · cited 1×
“[19] Inflammatory pathways are appealing because several agents target single or multiple inflammatory pathways.”
Background
Cited by
Hughes, D., Judge, C., Murphy, R., Loughlin, E., Costello, M., Whiteley, W., Bosch, J., O’Donnell, M. J., & Canavan, M. (2020) · JAMA · doi:10.1001/jama.2020.4249 · Cited by 472
Self-citationEvaluation of Adiposity and Cognitive Function in Adults
Anand, S. S., Friedrich, M. G., Lee, D. S., Awadalla, P., Després, J. P., Desai, D., de Souza, R. J., Dummer, T., Parraga, G., Larose, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46324 · Cited by 125
Self-citationArtificial intelligence for dementia prevention
Newby, D., Orgeta, V., Marshall, C. R., Lourida, I., Albertyn, C. P., Tamburin, S., Raymont, V., Veldsman, M., Koychev, I., Bauermeister, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13463 · Cited by 42
“133 Regarding non-pharmacological interventions, multiple studies have reported physical activity, cognitive reserve, 134 Mediterranean diet, 135 antioxidants, 136,137 and some vitamins (e.g., vitamin D 138,139 ) as protective factors for the development of dementia.”
BackgroundBrain Reserve, Resilience, and Cognitive Stimulation Across the Lifespan
Sorond, F. A., & Gorelick, P. B. (2023) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.08.003 · Cited by 8
Self-citation
Metadata
- Authors
- Whiteley, W. N., Anand, S., Bangdiwala, S. I., Bosch, J., Canavan, M., Chertkow, H., Gerstein, H. C., Gorelick, P., O’Donnell, M., Paré, G., Pigeyre, M., Seshadri, S., Sharma, M., Smith, E. E., Williamson, J., Cukierman-Yaffe, T., Hart, R. G., & Yusuf, S.
- Venue
- Age and Ageing
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-12
- Volume
- 49
- Issue
- 2
- Pages
- 154-160
- ISSN
- 0002-0729 (ISSN-L)
- 1468-2834
- OpenAlex
- W2995150464
- Cited by
- 23
- References
- 19
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Are large simple trials for dementia prevention possible? https://app.cochat.ai/papers/10.1093/ageing/afz152
- The paper
- Whiteley, W. N., Anand, S., Bangdiwala, S. I., Bosch, J., Canavan, M., Chertkow, H., Gerstein, H. C., Gorelick, P., O’Donnell, M., Paré, G., Pigeyre, M., Seshadri, S., Sharma, M., Smith, E. E., Williamson, J., Cukierman-Yaffe, T., Hart, R. G., & Yusuf, S. (2020). Are large simple trials for dementia prevention possible? Age and Ageing. https://doi.org/10.1093/ageing/afz152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.